{
  "Cluster": "5",
  "CandidateSubtype": "mixed",
  "TopGenes": [
    "FTH1",
    "IL8",
    "HLA-B",
    "SRGN",
    "IL1B",
    "HLA-DRA",
    "CTSB",
    "B2M",
    "TNFAIP3",
    "SOD2",
    "CD74",
    "PSAP",
    "NFKBIA",
    "S100A9",
    "NAMPT",
    "HBB",
    "HLA-DRB1",
    "VIM",
    "TMSB4X",
    "PLAUR"
  ],
  "ProliferationScore": "0.204 (low)",
  "StemnessScore": "0.780 (high)",
  "ImmuneScore": "1.000 (high)",
  "PrognosticScore": "0.126 (low)",
  "SupportingEvidence": [
    "Dominant antigen-presenting cell signature: HLA-DRA/DRB1, HLA-B, B2M, CD74",
    "Pro-inflammatory myeloid markers: IL1B, IL8, S100A9; NF-\u03baB regulators TNFAIP3, NFKBIA",
    "Lysosomal/stress and granule programs: CTSB, PSAP, SRGN, SOD2, NAMPT",
    "Migration/invasion-associated markers: VIM, PLAUR",
    "HBB likely reflects erythrophagocytosis or ambient RNA",
    "Profile indicates tumor-associated myeloid cells rather than malignant hepatoblasts; HB subtype not directly inferable from this cluster"
  ],
  "SuggestedExperiments": [
    "Validate cell identity by IHC/flow (CD68, CD163, HLA-DR) and lack of EPCAM/ALB/KRT8/18",
    "Infer CNVs from scRNA-seq to distinguish malignant vs immune populations",
    "Re-cluster EPCAM+/ALB+ tumor cells separately to assign HB subtype",
    "Apply spatial transcriptomics or multiplex IHC to map myeloid infiltration",
    "Measure IL1B/IL8 secretion and assess myeloid polarization states"
  ]
}